Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study

Southern African Journal of HIV Medicine

 
 
Field Value
 
Title Incidence of hepatitis C virus infection among people living with HIV: An Egyptian cohort study
 
Creator Elrashdy, Fatma Haga, Suzan Mohamed, Rahma Abdel Alem, Shereen Meshaal, Safa Cordie, Ahmed Elsharkawy, Aisha Esmat, Gamal
 
Subject — incidence rate of HCV; HCV screening; people living with HIV; Egypt; IDU; HCV seroconversion
Description Background: Egypt used to have one of the highest hepatitis C virus (HCV) infection prevalence rates worldwide, with an estimated HCV prevalence of around 4.5% to 6.7%.Objectives: To determine the HCV infection incidence rate amid Egyptian patients living with HIV.Method: A total of 460 HIV-positive patients were recruited in a retrospective cohort study from Imbaba Fever Hospital, Cairo, between January 2016 and March 2019. The patients had a negative baseline and at least one other HCV antibody test. Hepatitis C virus antibody testing was done by antibody sandwich third-generation enzyme-linked immunosorbent assay. The hepatitis C virus infection incidence rate among HIV-infected patients was calculated using the person-time incidence rate.Results: Two hundred and eighteen patients were finally included: 146 (31.7%) patients were excluded for having a positive baseline HCV Ab result and 96 patients were excluded for not having a follow-up HCV Ab test. Eighteen patients had HCV seroconversion (8.3%), achieving an incidence rate of 4.06 cases per 100 person-years (95% confidence interval: 3.87–4.24). Injection drug use (IDU) was the commonest risk factor among seroconverters, with an HCV incidence rate of 7.08 cases per 100 person-years. Injection drug use history was reported in 83.3% of the seroconverters and in only 47.2% of non-seroconverters; P = 0.005.Conclusion: Egyptian HIV-infected patients show a high incidence rate of HCV infection especially among those who have a history of IDU. Accordingly, attention should be paid for prevention, screening and timely treatment of HCV in patients infected with HIV.What this study adds: The demonstration of a high HCV infection incidence rate among HIV-infected patients and shows the need for screening and prevention in this population.
 
Publisher AOSIS
 
Contributor
Date 2022-11-09
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajhivmed.v23i1.1442
 
Source Southern African Journal of HIV Medicine; Vol 23, No 1 (2022); 5 pages 2078-6751 1608-9693
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajhivmed.org.za/index.php/hivmed/article/view/1442/2945 https://sajhivmed.org.za/index.php/hivmed/article/view/1442/2946 https://sajhivmed.org.za/index.php/hivmed/article/view/1442/2947 https://sajhivmed.org.za/index.php/hivmed/article/view/1442/2948
 
Coverage — — —
Rights Copyright (c) 2022 Fatma Elrashdy, Suzan Hagag, Rahma Mohamed, Shereen Abdel Alem, Safa Meshaal, Ahmed Cordie, Aisha Elsharkawy, Gamal Esmat https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT